Connect with us
European Gaming Congress 2024

Artificial Intelligence

Protein Expression Technology Market value of around US$ 3.97 Bn as of 2029 – Comprehensive Research Report by FMI

Published

on

DUBAI, United Arab Emirates, March 02, 2022 (GLOBE NEWSWIRE) — The global protein expression technology market was valued US$ 2.3 Bn in 2021, and is expected to increase at a CAGR of 7.3% during the forecast period of 2022-2029.

Market Outlook:

 Data Points Market Insights
Market Value 2021 US$ 2.3 Bn
Market Value 2029 US$ 3.97 Bn
CAGR 2022-2029 7.3%  
Market Share of Top 5 Countries 60.8%  
Key Market Players Lonza AG, Bio-Rad Laboratories, Inc, Thermo Fisher Scientific, Inc, Agilent Technologies, Inc, QIAGEN N.V, Takara Bio, Inc, Fujifilm Diosynth Biotechnologies USA, Inc, Genscript Biotech Corporation, Promega Corporation, Hudson Robotics Inc, Lucigen Corporation, New England Biolabs, Inc, Merck Millipore, GeneCopoeia, Inc, Bioneer Corporation and Oxford Expression Technologies Ltd

The global protein expression technology market is projected to experience significant growth during the forecast period, due to the growing demand for proteomics for the identification of several proteins that help in drug discovery, diseases diagnosis, and development of target-specific drugs.

Request for Report Sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-1540

There is growing demand for protein expression technology in multiple industries for numerous applications such as biologics production, therapeutic protein production, and research application.

Advertisement
Stake.com

“Increasing focus on cancer research and accurate identification of proteins associated with diseases, coupled with application of protein expression technology in the development of personalized medicines that are more effective for an individual will create lucrative opportunities for the global protein expression technology market in the future.”

Key Takeaways from Protein Expression Technology Market Study

  • There is steady demand for mammalian expression systems, as these offer exceptionally high-yield protein with a wide array of applications such as protein structural analysis and antibody production.
  • FMI reports that, North America is anticipated to be a prominent market for protein expression technology, owing to developed biotechnology infrastructure, favorable government policies, financial grants for laboratory research, and increase in R&D investments.
  • Reagents such as antibodies, oligomers, etc., are widely used in protein expression technology for desired transformation of an organic substance, finds FMI.
  • The commercial success of the protein expression technology market is highly dependent on cancer research studies, which could serve multiple purposes such as identification of proteins associated with diseases, presence of necrotic agents, and assessment of structural and functional abnormalities in protein anatomy.

Speak to our Research Expert: https://www.futuremarketinsights.com/ask-question/rep-gb-1540

Strategic Partnerships to Lend Winning Imperatives for Market Participants

The key players are focusing on collaborations, territorial expansion, mergers, and acquisitions to increase their share in the global protein expression technology market space. Mergers and acquisitions help them expand their existing product portfolio and topographical reach.

For example, to strengthen its life science business, Thermo Fisher Scientific Inc. acquired Life Technologies Corporation, which incorporates cutting-edge proteomics and genomics innovations. Increasing regulatory approvals for biologics and technological advancements have prompted high demand for innovative products.

Advertisement
Stake.com

Buy Now Report Here – https://www.futuremarketinsights.com/checkout/1540

Report Scope As Per Protein Expression Technology Industry Analysis

Attribute Details
Forecast Period 2022-2029
Historical Data Available for 2014-2021
Market Analysis US$ Mn for Value
Key Regions Covered North America, Latin America, Western Europe, Eastern Europe, Japan, APEJ and Middle East and Africa
Key Countries Covered US, Canada,  Brazil,  Mexico, Germany, U.K., France, Italy, Spain, Nordic, BENELUX, Poland, Russia, China, Japan, India, Australia, New Zealand, GCC Countries, and South Africa
Key Market Segments Covered Expression Systems, Product, Application, End User and Region
Key Companies Profiled • Lonza AG

• Bio-Rad Laboratories, Inc

• Thermo Fisher Scientific, Inc

Advertisement
Stake.com

• Agilent Technologies, Inc

• QIAGEN N.V

• Takara Bio, Inc

• Fujifilm Diosynth Biotechnologies USA, Inc

• Genscript Biotech Corporation

Advertisement
Stake.com

• Promega Corporation

• Hudson Robotics Inc

• Lucigen Corporation

• New England Biolabs, Inc

• Merck Millipore

Advertisement
Stake.com

• GeneCopoeia, Inc

• Bioneer Corporation

• Oxford Expression Technologies Ltd

Request Customization Protein Expression Technology Market Report

More Valuable Insights on Protein Expression Technology Market

Future Market Insights brings a comprehensive research report on forecasted revenue growth at global, regional, and country levels, and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2029. The global protein expression technology market is segmented in detail to cover every aspect of the market, and present a complete market intelligence approach to the reader.

Advertisement
Stake.com

The study provides compelling insights on the protein expression technology market on the basis of expression system (insect cell expression systems, prokaryotic expression systems, mammalian expression systems, and yeast expression systems), product type (expression vectors, reagents, competent cells, and instruments), application (drug discovery, protein purification, protein therapeutics, and diseases diagnostic & monitoring), and end user (biotechnology companies, pharmaceutical companies, contract research organizations, and academic research institutes), across seven major regions.

Explore FMI’s Extensive ongoing Coverage on Healthcare Domain

Surgical Sutures Market: The surgical sutures market is likely to attain a CAGR of 5.4% during the forecast period, up from US$ 4.35 Bn in 2019 to reach a valuation of US$ 6 Bn by 2027.

Respiratory Measurement Devices Market: The respiratory measurement devices market is anticipated to record a CAGR of 7.2% during the forecast period 2022-2032.

Radiology Information System RIS Market: The Radiology Information System market is projected to register a CAGR of 7.6% during the forecast period, up from US$ 809.8 million in 2020 to reach a valuation of US$ 1,315.6 million by 2026.

Advertisement
Stake.com

Nuclear Imaging Devices Market: The nuclear imaging devices market is likely to record a CAGR of 5% during the forecast period, up from US$ 2.6 Bn in 2020 to reach a valuation of US$ 3.4 Bn by 2025.

Biochemicals Control Market: The biochemicals control market is expected to grow from US$ 2 Bn in 2021 and progressing at a CAGR of 12.7% during the forecast Period.

Disposable Medical Sensors Market: The disposable medical sensors market is expected to grow at a CAGR of 8.1% over the forecast period, from USD 6.5 billion in 2021 to USD 9.4 billion in 2026.

Surgical Navigation System Market: The surgical navigation system market is projected to attain a CAGR of 6.2% during the forecast period, up from US$ 940 Mn in 2020 to reach a valuation of US$ 1,700 Mn by 2030. 

Artificial Pancreas Device System Market: During the forecast period, the artificial pancreas device system market is expected to advance at a rapid pace with a CAGR of 18.2%.

Advertisement
Stake.com

Pharmaceuticals Excipients Market: The pharmaceuticals excipients market is expected to register a CAGR of 6% during the forecast period, up from US$ 7.9 Bn in 2021 to reach a valuation of US$ 10.9 Bn by 2026.

Computed Tomography Market: The computed tomography market is likely to register a CAGR of 5.5% during the forecast period, up from US$ 5.6 Bn in 2020 to reach a valuation of US$ 9.9 Bn by 2030. 

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact:
Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: [email protected]
For Media Enquiries: [email protected]
Website: https://www.futuremarketinsights.com/
Report:https://www.futuremarketinsights.com/reports/protein-expression-technology-market
Press Release Source: https://www.futuremarketinsights.com/press-release/protein-expression-technology-market

Advertisement
Stake.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Transforming Healthcare with AI: Yidu Tech’s Gong Rujing at Summer Davos

Published

on

transforming-healthcare-with-ai:-yidu-tech’s-gong-rujing-at-summer-davos

DALIAN, China, July 1, 2024 /PRNewswire/ — “AI in healthcare is extremely challenging. For companies, it requires not only solving scientific problems but also understanding AI technology and respecting the complexity of the healthcare industry.” At the 15th Annual Meeting of the New Champions, also known as Summer Davos, Ms. Gong Rujing (Yingying), Chairwoman and Founder of Yidu Tech, was invited as a distinguished representative of the healthcare technology sector. She shared her unique insights into the future of AI in healthcare during the thematic dialogue on “Healthcare Analytics, Not Moving Fast Enough.”

This year marks the 10th anniversary of Yidu Tech and Ms. Gong Rujing’s decade-long dedication to the healthcare industry. From the inception of her entrepreneurial journey 10 years ago, she has been driven by the mission to leverage the power of technology to deliver precise healthcare to every individual.
Ms. Gong described the past decade as a journey filled with miracles and achievements. During this period, Yidu Tech has progressively established close collaborations with key stakeholders in the healthcare industry, including government agencies, hospitals, pharmaceutical companies, insurance firms, experts, and clinicians. As of March 31, 2024, Yidu Tech’s “AI Medical Brain” YiduCore has been authorized to process and analyze over 5 billion medical records, covering more than 2,500 hospitals.
In AI-powered clinical research, Yidu Tech has supported researchers and clinicians in producing over 240 high-level papers, accelerating the application of research outcomes. Additionally, Yidu Tech provides clinical trial services to globally renowned pharmaceutical companies, helping them optimize trial processes, reduce costs, and bring new drugs to market more swiftly, ultimately benefiting patients. In healthcare management, Yidu Tech’s AI technology plays a crucial role by analyzing vast amounts of medical data to provide comprehensive decision support to healthcare administrators, helping them optimize resource allocation and improve service efficiency.
“We are now entering a new era of AI technology.” The development of large language model technologies has opened up new possibilities across various industries. Yidu Tech has independently developed a large language model specific to the medical field and is advancing its application across the entire healthcare industry chain. The goal is to promote further progress and innovation through new AI technologies. However, Ms. Gong also emphasized that the healthcare industry is professional, complex, and sensitive, and the application of new technologies must address challenges such as data security, privacy protection, and ethics.
“Data security and privacy protection are fundamental to the development of AI technology and medical big data technology. We must ensure that all stakeholders are satisfied with compliance, security, accessibility, and privacy protection.”
“AI technology still has a long way to go.” She called on policymakers, healthcare institutions, and technology companies to work together to realize the immense potential of healthcare data. Ms. Gong highlighted that building trust is key, and enhancing data operability is essential to fully unleash the power of data. “It’s not just about better data quality; it’s about a better future for health.”

View original content:https://www.prnewswire.co.uk/news-releases/transforming-healthcare-with-ai-yidu-techs-gong-rujing-at-summer-davos-302186561.html

Continue Reading

Artificial Intelligence

Yidu Tech’s FY2024 results: existing business achieves first full-year profit on adjusted EBITDA

Published

on

yidu-tech’s-fy2024-results:-existing-business-achieves-first-full-year-profit-on-adjusted-ebitda

HONG KONG, July 1, 2024 /PRNewswire/ — On June 27, 2024, Yidu Tech Inc. (the ”Company” or ”Yidu Tech”) (2158.HK), a leader in China’s AI medical industry, announced its results for the 2024 fiscal year. During the reporting period, the Company recorded revenue of RMB 807.1 million. Gross profit margin in FY2024 increased to 42.1% from 34.1% in FY2023, representing an increase of 8 percentage points, hitting a record high. Adjusted net loss narrowed from RMB 448.7 million in FY2023 to RMB158.1 million, down 64.8% year-on-year. The management of Yidu Tech said at the annual results conference the next day that excluding strategic investments in proprietary large language model, non-cash items, and non-operating items, the adjusted EBITDA for our current business has achieved profit, moving from a RMB 327 million loss to a profit of RMB 31.1 million for the first time this fiscal year.

Management added that as of market close on June 27, the Company’s P/B ratio has decreased to 1.06. Not including the valuation of its domestic and international businesses, its market value is still lower than its fund reserves on hand. As such, management believes that the Company’s share price is still severely undervalued. Notably, renowned sovereign fund BIA has continually increased its shareholding of Yidu Tech by 21.50% over the past two months. The management is confident in the Company’s long-term growth potential and hopes to continually create innovative technologies and increase returns to its shareholders.
In FY2024, Yidu Tech focused on its core business, improving internal operating efficiency and earning quality. Among its earnings, revenue from its big data platform and solutions segment reached RMB 313.6 million, an increase of 41.4% year-on-year. Revenue from its life science solutions segment reached RMB 324.0 million, up 28.1% year-on-year and the gross margin increased by 14.6 percentage points to a historical high of 32.1%. Revenue from its health management platform and solutions segment reached RMB 169.5 million, and the gross profit margin of this segment was 58.1%, representing a year-on-year increase of 17.4 percentage points.
During the reporting period, the Company has continued the development and training of large language model in the medical vertical field based on 500 billion fine-trained Tokens, with model training for 6B, 13B, and 70B parameters completed.

View original content:https://www.prnewswire.co.uk/news-releases/yidu-techs-fy2024-results-existing-business-achieves-first-full-year-profit-on-adjusted-ebitda-302185986.html

Continue Reading

Artificial Intelligence

Lucinity’s AI Innovation Recognized at Microsoft’s Prestigious Global Partner Awards 2024

Published

on

lucinity’s-ai-innovation-recognized-at-microsoft’s-prestigious-global-partner-awards-2024

REYKJAVIK, Iceland, June 28, 2024 /PRNewswire/ — Lucinity has been recognized as a finalist in the AI Innovation category at the prestigious Microsoft Global Partner Awards 2024, recognizing its breakthrough AI solution and contribution to financial security through its collaboration with Microsoft. 

Lucinity beat more than 4,700 companies to be named a finalist at the annual Microsoft Global Partner Awards, which highlights Lucinity’s achievements as a Microsoft partner in optimizing business processes, improving customer experiences, and opening new pathways for digital transformation.
This achievement comes in addition to winning two prestigious awards at Microsoft Partner Awards 2024 last month, including Partner of the Year – Iceland, and the Sustainability and Social Impact award.
The accolade recognizes Lucinity’s significant advancements in AI for financial crime operations, particularly through their AI-powered copilot, Luci. This innovative solution utilizes Microsoft Azure OpenAI technology to integrate advanced generative AI into financial crime investigations and regulatory compliance, optimizing processes and saving significant time and resources for financial institutions.
The Lucinity platform streamlines compliance, provides instant insights, and reduces typical investigation times from three hours to just 30 minutes. The technology can also save financial institutions an estimated $100 million in productivity savings, as well as savings in training and recruitment.
Microsoft comments on Lucinity’s award recognition, saying “Financial crime profoundly impacts our global community, with far-reaching economic, security, and social implications. It can harm a country’s reputation and increase exposure to criminal activities, emphasizing the critical need for robust anti-money laundering initiatives and persistent vigilance. Lucinity, with their innovative AI solutions, has really tried to combat this huge global challenge. They use ‘Human AI’ to enhance financial crime prevention, combining AI with human expertise for efficient, user-friendly solutions. Additionally, Lucinity has developed a tool called Luci, an AI-powered copilot that helps transform financial crime prevention from a process that took hours to one that takes minutes.”
“Being recognized as a finalist at the Microsoft Global Partner Awards is  validation of our impactful collaboration with Microsoft in financial crime operations. Our partnership has been pivotal for our innovations, enabling us to use Azure OpenAI to bring tools like Luci to life and deliver impactful results for our clients,” says Guðmundur Kristjánsson, Founder & CEO of Lucinity.
Contact:Name: Celina PabloEmail: [email protected]: +354 792 4321
Logo: https://mma.prnewswire.com/media/2208676/4669079/Lucinity_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/lucinitys-ai-innovation-recognized-at-microsofts-prestigious-global-partner-awards-2024-302186091.html

Continue Reading

Trending